Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib

References

• Rowley J D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293
   PubMed Web of Science ®Google Scholar
• Morris S W, Daniel L, Ahmed C M, Elias A, Lebowitz P. Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood 1990; 75: 2035–2041
   PubMed Web of Science ®Google Scholar
• Hagemeijer A, Buijs A, Smit E, Janssen B, Creemers G J, Van der Plas D, et al. Translocation of BCR to chromosome 9: a new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia. Genes Chromosomes Cancer 1993; 8: 237–245
   PubMed Web of Science ®Google Scholar
• Loncarevic I F, Römer J, Starke H, Heller A, Bleck C, Ziegler M, et al. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia. Genes Chromosomes Cancer 2002; 34: 193–200
   PubMed Web of Science ®Google Scholar
• Dewald G W, Wyatt W A, Juneau A L, Carlson R O, Zinsmeister A R, Jalal S M, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998; 91: 3357–3365
   PubMed Web of Science ®Google Scholar
• Dewald G W, Wyatt W A, Silver R T. Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy. Leuk Lymphoma 1999; 34: 481–491
   PubMed Web of Science ®Google Scholar
• Kolomietz E, Al-Maghrabi J, Brennan S, Karaskowa J, Minkin S, Lepton J, et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001; 97: 3581–3588
   PubMed Web of Science ®Google Scholar
• Storlazzi C T, Giorgina S, Anelli L, Albano F, Pastore D, Zagaria A, et al. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chromosomes Cancer 2002; 35: 271–276
   PubMed Web of Science ®Google Scholar
• Zagaria A, Anelli L, Albano F, Vicari L, Schiavone E M, Annunziata M, et al. Molecular cytogenetic characterization on der(9) in chronic myeloid leukemia. Cancer Genet Cytogenet 2006; 167: 97–102
   PubMed Web of Science ®Google Scholar
• Sinclair P B, Nacheva E P, Leversha M, Telford N, Chang J, Reid A, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738–743
   PubMed Web of Science ®Google Scholar
• Huntly B JP, Reid A G, Bench A J, Campbell L J, Telford N, Shepherd P, et al. Deletions of the derivative 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98: 1732–1738
   PubMed Web of Science ®Google Scholar
• Kolomietz E, Al-Maghrabi J, Brennan S, Karaskowa J, Minkin S, Lepton J, et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001; 97: 3581–3588
   PubMed Web of Science ®Google Scholar
• Gribble S M, Sinclar P B, Grace C, Gren A R, Natcheva E P. Comparative analysis of G banding, chromosome painting, locus-specyfic FISH and CGH in chronic myeloid leukemia. Cancer Genet Cytogenet 1999; 11: 7–17
   Web of Science ®Google Scholar
• Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002; 107: 76–94
   PubMed Web of Science ®Google Scholar
• Zaccaria A, Valenti A M, Donti E, Gozzetti A, Ronconi S, Spedicato F, et al. Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. Haematologica 2007; 92: 564–565
   PubMed Web of Science ®Google Scholar
• Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010–4022
   PubMed Web of Science ®Google Scholar
• Sokal J E, Cox E B, Baccarani M, Tura S, Gomez G A, Robertson J E, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63: 789–799
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, Allan N C, Baccarani M, Kluin-Nelemans J C, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon α. Writing committee for the collaborative CML prognostic factors project group. J Natl Cancer Inst 1998; 90: 850–858
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006; 108: 1809–1820
   PubMed Web of Science ®Google Scholar
• Huntly B JP, Guilhot F, Reid A G, Vassiliou G, Hennig E, Franke C, et al. Imatinib improves but not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003c; 102(6)2205–2212
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, et al. Imatinib mesylate therapy may overcome the poor prognosis significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005; 105: 2281–2285
   PubMed Web of Science ®Google Scholar
• ISCN. An International System for Human Cytogenetic Nomenclature. L G Shaffer, N Tommerup. S. Karger, Basel 2005
   Google Scholar
• Preizner W, Sacha T, Salamanczuk Z, Pienkowska-Grela, Haus O, Hellmann A. Standard of diagnostic and therapeutic procedures in patients with chronic myeloid leukemia in Poland in 2007. Acta Hematologica Polonica 2007; 30: 107–122
   Google Scholar
• Drucker B J, Guilhot F, O'Brien S G, Gathmann I, Kantarjian H, Gattermann N, et al. IRIS investigators: five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417
   PubMed Web of Science ®Google Scholar
• Guilhot F, on behalf of the IRIS Study Group. Sustained durability of responses plus high rates of cytogenetic responses result in long term benefit for newly diagnosed chronic phase chronic myeloid leukemia treated with Imatinib therapy: update from the IRIS study [abstract]. Blood 2004; 104: 10a
   Web of Science ®Google Scholar
• Simonsson B, on behalf of the IRIS Study Group. Beneficial effects of cytogenetic and molecular response on long term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM): update from the IRIS study [abstract]. Blood 2005; 106: 52a
   Web of Science ®Google Scholar
• Wang Y, Hopwood V L, Hu P, Lennon A, Osterberger J, Glassman A. Determination of secondary chromosomal aberrations of chronic myelocytic leukemia. Cancer Genet Cytogenet 2004; 153: 53–56
   PubMed Web of Science ®Google Scholar
• Barnes D J, Palaiologou D, Panousopoulou E, Schultheis B, Yong A S, Wong A, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005; 65: 8912–8919
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Hochhaus A, Baccarani M. European Leukemia Net. Chronic myeloid leukaemia. Lancet 2007; 370: 342–350
   PubMed Web of Science ®Google Scholar
• Pienkowska-Grela B, Woroniecka R, Solarska I, Kos K, Pastwinska A, Konopka L, et al. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukaemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript. Cancer Genet Cytogenet 2007; 174: 111–115
   PubMed Web of Science ®Google Scholar
• Di Bacco A, Keeshan K, McKenna S L, Cotter T G. Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis. Oncologist 2000; 5: 405–415
   PubMedGoogle Scholar
• Honda H, Ushijima T, Wakazono K, Oda H, Tanaka Y, Aizawa S, et al. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. Blood 2000; 95: 1144–1150
   PubMed Web of Science ®Google Scholar
• Wendel H G, de Stanchina E, Cepero E, Ray S, Emig M, Fridman J S, et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci USA 2006; 103: 7444–7449
   PubMed Web of Science ®Google Scholar
• Alenzi F Q, Wyse R K, Tamimi W G, Bamaga M S, Lotfy M A. A close link between Fas, p53 and Apaf-1 in chronic myeloid leukemia. Saudi Med J 2007; 28: 1119–1121
   PubMed Web of Science ®Google Scholar
• Huntly B JP, Bench A, Green A R. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003; 102: 1160–1168
   PubMed Web of Science ®Google Scholar
• Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G, et al. Subgroup of patients Philadelphia-positive chronic myelogenous leukemia characterised by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001; 128: 114–119
   PubMed Web of Science ®Google Scholar
• Aoun P, Wiggins M, Pickering D, Foran J, Rasheed H, Pavletic S Z, et al. Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis. Cancer Genet Cytogenet 2004; 154: 138–143
   PubMed Web of Science ®Google Scholar
• Zagaria A, Anelli L, Albano F, Vicari L, Schiavone E M, Annunziata M, et al. Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia. Cancer Genet Cytogenet 2006; 167: 97–102
   PubMed Web of Science ®Google Scholar
• Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A, Hehlmann R, et al. Chronic Myelogenous Leukemia (CML) Study Group. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007; 110: 1283–1290
   PubMed Web of Science ®Google Scholar
• Lee Y K, Kim Y R, Min H C, Oh B R, Kim T Y, Kim Y S, et al. Deletions of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia. Cancer Genet Cytogenet 2006; 166: 65–73
   PubMed Web of Science ®Google Scholar
• Fourouclas N, Campbell P J, Bench A J, Swanton S, Baxter E J, Huntly B J, et al. Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia. Haematologica 2006; 91: 952–955
   PubMed Web of Science ®Google Scholar
• Vaz de Campos M G, Montesano F T, Rodrigues M M, Chauffaille M. Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia. Cancer Genet Cytogenet 2007; 178: 49–56
   PubMed Web of Science ®Google Scholar
• Kim Y R, Cho H I, Yoon S S, Park S, Kim B K, Lee Y K, et al. Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra signal-FISH. Genes Chromosomes Cancer 2005; 43: 37–44
   PubMed Web of Science ®Google Scholar
• Pienkowska-Grela B, Woroniecka R, Doroszuk K, Rygier J, Pastwinska A, Grygalewicz B, et al. Frequency of submicroscopic deletion in fused BCR/ABL region by routine diagnostic method and with specific FISH probes in patients with chronic myeloid leukemia. Acta Hem Pol 2008; 39: 89–100
   Google Scholar
• Huntly B J, Guilhot F, Reid A G, Vassiliou G, Hennig E, Franke C, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003; 102: 2205–2212
   PubMed Web of Science ®Google Scholar
• Bernardeschi P, Fiorentini G, Rossi S, Dentico P, Simi P, Guidi S. Trisomy 8 in Philadelphia-negative cells during imatinib therapy. Am J Hematol 2004; 77: 88–89
   PubMed Web of Science ®Google Scholar
• Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C, et al. France Intergroupe pour la Leucemie Myeloide Chronique: report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004; 18: 1340–1346
   PubMed Web of Science ®Google Scholar
• Deininger M W, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007; 110: 1509–1519
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Gozzetti A, Galimberti S, Trawinska M M, Caravita T, Siniscalchi A, et al. Characterization of Ph-negative abnormal clones emerging during imatinib therapy. Cancer 2007; 109: 2466–2472
   PubMed Web of Science ®Google Scholar